Company intelligence / Profile preview
BiOneCure Therapeutics Inc.
Germantown, Maryland, United Statesbionecure.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BIO-106, an anti-Trop-2 ADC, is currently in Phase I/II clinical trials (StarBridge-1) to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity as monotherapy and in combination with pembrolizumab in patients with advanced cancers[6][8].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Nanjing Leads Biolabs
Beyond the preview
Go deeper on BiOneCure Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiOneCure Therapeutics Inc..